Managing the Case Following Diagnosis
Miia Kivipelto, MD, PhD, describes the value of an early diagnosis of Alzheimer’s disease alongside the disclosure of diagnosis and clinical management options for a patient who has been diagnosed with Alzheimer’s disease in the early stages. She also provides preliminary results from non-pharmacological intervention studies and describes the potential role of these interventions in the patient case study.
Key Learning Objectives for Biogen’s AAIC 2018 Symposium:
- Understand the importance and challenges of an early diagnosis of Alzheimer’s disease
- Broaden understanding of the use of neuropsychological tools and imaging and fluid biomarkers to leverage an earlier diagnosis of Alzheimer’s disease
- Highlight the value of biomarkers for assessing differential diagnosis across dementia etiologies
- Explore clinical management options for patients with a diagnosis of Alzheimer’s disease in the early stages, including current non-pharmacological interventions
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.